GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

GSK plc announced that the China National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy with ...

This compares to the £840 per dose (pre-discount) price of GSK's Nucala - though these actual prices are likely to be much closer together once their respective confidential discounts are ...

The 5-foot-11 senior point guard has been preparing for this role with coach Nareg Kopooshian since he was a youth and has led AGBU to a 16-2 start. High school basketball: Scores for boys’ and ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. On this page, we're recording the regulatory progress of in-market products, including expansions into key geographies and ...

GSK’s Nucala was approved in the US for severe asthma with an eosinophilic phenotype treatment. Credit: MAXSHOT.PL / Shutterstock. The China National Medical Products Administration (NMPA) has ...

London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy ...